Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera. After emerging from stealth with a $290 ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Metsera cleared that benchmark Monday, with a jump from 78 to 82 Monday. Please watch the video at ...

Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now ...

So far this year, 11 U.S. venture-backed private companies have gone public or agreed to be acquired at valuations of $1 billion or more, per Crunchbase data. That’s more than double the number from ...

KB Home Posts Downbeat Results, Joins UniFirst, Oklo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Science Applications Posts Better-Than-Expected Earnings, Joins Qifu ...

Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $2.68 billion, has disclosed the approval of 2024 annual cash bonuses for its named executive officers, following ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic ...

We expect 2025 to be another year of execution and growth, as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” Pipeline ...

We expect 2025 to be another year of execution and growth, as we rapidly advance Metsera's portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” MET-097i is a fully ...